Certara Q3 2026 Revenue Rises 4% on Software Growth

Certara Inc. (NASDAQ: CERT) reported higher third-quarter 2026 revenue and adjusted EBITDA from continuing operations, as growth in its software business offset a decline in services revenue. The company also outlined full-year revenue growth of 2% to 3% and adjusted diluted earnings per share of $0.31 to $0.34.

Revenue for the quarter ended at $94.9 million, up 4% from $90.9 million a year earlier. Software revenue increased to $48.8 million from $43.8 million, while services revenue declined to $46.1 million from $47.1 million.

Certara recorded a GAAP net loss from continuing operations of $3.6 million, compared with a loss of $4.8 million in the prior-year quarter. Diluted loss per share narrowed to $0.02 from $0.03. Adjusted diluted EPS was $0.09, unchanged from a year earlier.

Adjusted EBITDA rose 6% to $30.2 million from $28.6 million. The adjusted EBITDA margin increased to 31.8% from 31.5%, with the latest figure reflecting shared corporate costs retained after the divestiture of the Regulatory and Medical Writing business.

Bookings increase on a trailing 12-month basis

Net bookings, excluding the divested Regulatory and Medical Writing operation, totaled $92.5 million in the third quarter, up from $88.6 million a year earlier. Software bookings rose to $46.9 million from $40.8 million, while services bookings fell to $45.6 million from $47.8 million.

Trailing 12-month net bookings increased 2% to $409.2 million from $399.5 million. Software bookings for that period rose to $202.4 million from $187.8 million, partly offset by a decrease in services bookings to $206.8 million from $211.7 million.

2026 outlook

Certara expects 2026 revenue growth of 2% to 3%, excluding the Regulatory and Medical Writing business. It projects a fourth-quarter adjusted EBITDA margin of 29% to 31% and full-year adjusted diluted EPS of $0.31 to $0.34.

The outlook assumes 155 million to 157 million fully diluted shares and a tax rate of 25% to 30%. Certara did not reconcile its forward-looking adjusted EBITDA margin or adjusted EPS guidance to comparable GAAP measures, citing limited visibility and potential variability in acquisition, financing and stock-compensation costs.

The company completed the sale of its Regulatory and Medical Writing business to Veristat on May 8, 2026, under an agreement providing consideration of up to $135 million. The operation’s 2026 results will be classified as discontinued operations; revenue through the closing date was $19.2 million.

Certara identified several uncertainties that could affect future performance, including resistance to model-informed biopharmaceutical development, competition, changes or delays in industry regulation, trends in research and development spending, government-agency disruptions and funding constraints, industry consolidation, and its ability to expand customer relationships and enter new markets.